Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study.

Autor: Samples L; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Voutsinas J; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Fakhri B; Division of Hematology and Oncology, University of California, San Francisco, CA., Khajavian S; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Spurgeon S; Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR., Stephens D; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT., Skarbnik A; Novant Health, Charlotte, NC., Mato A; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Broome C; Division of Hematology and Oncology, Georgetown University, Washington, DC., Gopal A; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Smith S; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Lynch R; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Rainey M; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Kim MS; Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR., Barrett-Campbell O; Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH., Hemond E; Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH., Tsang M; Division of Hematology and Oncology, University of California, San Francisco, CA., Ermann D; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, UT., Malakhov N; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY., Rao D; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Shakib-Azar M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Morrigan B; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Chauhan A; Division of Hematology and Oncology, Georgia Cancer Center, Augusta University, Augusta, GA., Plate T; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Gooley T; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Ryan K; AstraZeneca, Gaithersburg, MD., Lansigan F; Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH., Hill B; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Pongas G; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Parikh SA; Department of Hematology, Mayo Clinic, Rochester, MN., Roeker L; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY., Allan JN; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY., Cheng R; Division of Cardiology, University of Washington, Seattle, WA., Ujjani C; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Division of Hematology and Oncology, University of Washington, Seattle, WA.

Publikováno v: Blood advances [Blood Adv] 2024 May 14; Vol. 8 (9), pp. 2085-2093.